Because innovation fuels our pipeline

LNTH-2401 is a novel radiodiagnostic targeting the gastrin-releasing peptide receptor.

LNTH-2402 is a novel gastrin-releasing peptide receptor targeted radiotherapeutic for solid tumors including prostate, breast, lung and other cancers.

PNT2003 is a somatostatin receptor targeted radiotherapeutic, in development for gastroenteropancreatic neuroendocrine tumors.

LNTH-2501/EVG-001 is an investigational kit for the preparation of Gallium-68 DOTATOC which may be used in conjunction with a PET scan to stage and localize SSTR+ neuroendocrine tumors in adults and children.

LNTH-1363S is a fibroblast activation protein, copper-64 labeled radiodiagnostic with broad potential imaging applicability and use in oncology.

LNTH-2403 is a Leucine-Rich Repeat-Containing Protein 15 targeted radiotherapeutic. It received Orphan Drug and Rare Pediatric Disease designations from the U.S. FDA for the treatment of osteosarcoma.

LNTH-2404 is a Trophoblast cell surface antigen-2 targeted radiotherapeutic.

LNTH-2503/EVG-321 is a highly specific peptide vector, which binds to the cholecystokinin-2 receptor (CCK2), a highly expressed tumor marker in cancers like small cell lung cancer (SCLC).

LNTH-2505/EVG-311 is a molecularly targeted tracer that binds to a glial cell surface molecule which may be used for the diagnosis and treatment of glioblastoma (GBM) and potentially other glial tumors.

LNTH-2507/EVG-332 is a radiotracer targeting a cell surface molecule for the treatment of pancreatic ductal adenocarcinoma (PDAC).

LNTH-2509/EVG-341 is a radiotracer targeting a cell surface molecule for the treatment of lobular breast cancer.

Florquinitau is a next-generation tau-targeting radiodiagnostic for Alzheimer’s disease.

Flutafuranol is a next-generation ß amyloid-targeting radiodiagnostic for Alzheimer’s disease.

LNTH-2620/PI-2620 is a F-18 labeled small molecule specifically targeting tau used as radiodiagnostic in conjunction with PET imaging to show aggregated tau protein in people with Alzheimer’s disease and other tauopathies. It binds to both isoforms of tau (4R and 3R/4R repeats). The FDA has granted fast track designation for the development of LNTH-2620/PI-2620 in Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).

LNTH-2511/DED is a F-18 labeled small molecule specifically targeting reactive astrocytes during neuroinflammation, which presents in diseases such as Alzheimer’s Disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS) and Parkinson’s disease.

LNTH-2513/GP1 is a small F-18 labeled molecule, specifically designed to image active thrombi (new blood clots) by binding to activated GPllb/llla receptors, which are involved in thrombus formation and propagation. LNTH-2513/GP1 is the first PET tracer shown to be able to detect acute thromboembolic events in humans.

LNTH-2515/Florbetaben is a F-18 labeled radiodiagnostic stilbene derivative that binds to amyloid deposits and is being studied in patients with cardiac amyloidosis. The FDA has granted fast track designation for the development of LNTH-2515/Florbetaben imaging for the diagnosis of AL (amyloid light chain) and ATTR (transthyretin amyloid cardiomyopathy) cardiac amyloidosis.